Seelos Therapeutics Inc (SEELQ)

[eicoman]

great point DG, it's crazy how long drugs can take to be developed for many different reasons, the pathway for Femprox is very well defined and developed, it just has to wait for the Flib. decision and /or someone willing to finance the trials and give APRI a favorable deal. Vitaros success in EU will make Femprox look more attractive as well, especially when women start getting a double dose from their male partners and trying it, I could really see that happening in France if they get full reimbursement there, then the double dose cost is a not an issue.